Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Novartis Pharmaceuticals
Modality
UNKNOWN
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07630961CT.gov Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Invasive Ductal Breast Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| 68ga-dfc413 (this asset) | Novartis Pharmaceuticals | P1 | CC · 43 |
| Carboplatin | GBG Forschungs GmbH | P3 | BBB |
| Letrozole | University of Washington | P4 | BBB |
| Cyclophosphamide | UMC Utrecht | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | RenJi Hospital | P3 | BB |
| Pertuzumab | GBG Forschungs GmbH | P3 | BB |
| Trastuzumab | GBG Forschungs GmbH | P3 | BB |
| Epirubicin | GBG Forschungs GmbH | P3 | BB |
| Fulvestrant | G1 Therapeutics, Inc. | P3 | BB |
+27 more in the Invasive Ductal Breast Carcinoma cohort
Other indications for 68ga-dfc413
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Pancreatic Ductal Adenocarcinoma | — | P1 | CC · 43 |
| Invasive Lobular Breast Carcinoma | — | P1 | CC · 43 |
| Soft Tissue Sarcoma | — | P1 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. 68ga-dfc413 in Invasive Ductal Breast Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/68ga-dfc413-invasive-ductal-breast-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →